Observation of Blood Lipid Outcomes in Lipid Clinic

January 3, 2020 updated by: Mackay Memorial Hospital

Observation of Blood Lipid Outcomes in Patients Who Receive Treatment in Lipid Clinic of Taipei MacKay Memorial Hospital

Taipei MacKay Memorial Hospital will establish a Lipid Clinic for hyperlipidemic patients. In this Lipid Clinic, the physician will discuss with each individual patient and set an individualized LDL goal according to current guideline and regulation of National Health Insurance Administration (NHIA). The aim of this study is to observe blood lipid outcomes in patients who receive treatment in Lipid Clinic of Taipei MacKay Memorial Hospital.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Hyperlipidemia is a major risk factor of atherosclerotic cardiovascular disease (ASCVD), and therefore it is beneficial to prevent the risk of ASCVD by controlling the prevalence of hyperlipidemia. According to CEPHEUS Pan-Asia survey, the rate of LDL goal attainment in hyperlipidemic patients of Taiwan was suboptimal, especially in high-risk patients. 2017 Taiwan lipid guideline for high-risk patients has been published and clearly defined the treatment goal of blood LDL-C for high-risk patients. Besides, Taipei MacKay Memorial Hospital will establish a Lipid Clinic for hyperlipidemic patients. In this Lipid Clinic, the physician will discuss with each individual patient and set an individualized LDL goal according to current guideline and regulation of National Health Insurance Administration (NHIA). The aim of this study is to observe blood lipid outcomes in patients who receive treatment in Lipid Clinic of Taipei MacKay Memorial Hospital.

Study Type

Observational

Enrollment (Anticipated)

500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Chao-Feng Lin, PhD
  • Phone Number: 3256 886-2-25433535
  • Email: thcpci@gmail.com

Study Locations

  • Taiwan
      • Taipei, Taiwan, 104
        • Recruiting
        • Taiwan, Taipei, Mackay Memorial hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients who are ≥20 years, have abnormal lipid profiles, need lipid-lowering drugs according to 2017 Taiwan Lipid Guideline in Lipid Clinic of Taipei MacKay Memorial Hospital.

Description

Inclusion Criteria:

  • ≥20 years-old
  • Abnormal lipid profiles according to 2017 Taiwan Lipid Guideline for High-risk Patients

Exclusion Criteria

  • Reject to participate in this study
  • Pregnant women
  • Prisoner
  • Illiteracy
  • HIV patients
  • Individuals who are mentally retarded, homeless, and handicapped

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Other

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Dyslipidemic patients
Patients who meet the criteria of high-risk category according to 2017 Taiwan Lipid Guideline for High-Risk Patients have a abnormal serum LDL-C level
Other: Education and inform the optimal threshold of LDL-C levels
Physicians educate patients and provide a clear information about optimal LDL-C value according to individual patient's condition according to current guidelines

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Lipid profile
Time Frame: 12 month
check serum level of LDL-C
12 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Mackay Memorial Hospital

Collaborators

Amgen

Investigators

  • Principal Investigator: Chao-Feng Lin, PhD, Mackay Memorial Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

January 3, 2020

Primary Completion (Anticipated)

December 31, 2020

Study Completion (Anticipated)

December 31, 2025

Study Registration Dates

First Submitted

December 26, 2019

First Submitted That Met QC Criteria

January 3, 2020

First Posted (Actual)

January 7, 2020

Study Record Updates

Last Update Posted (Actual)

January 7, 2020

Last Update Submitted That Met QC Criteria

January 3, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 18MMHIS083e

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

We will not provide IPD to other researchers according to IRB regulation.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dyslipidemias

Clinical Trials on Education and inform the optimal threshold of LDL-C levels

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe